New cancer drugs only slightly better than accreditation

Another study has found that most new cancer medicines are massively expensive and rather useless.  Read it here: Harrison P. Another Analysis Questions Efficacy of New Cancer Drugs.

That’s better evidence of a stronger effect than is available for ISO accreditation. Other cancer studies cited in the article enable authors to say that most of the drugs are inappropriate, unethical and should be stopped. 

Just like UKAS accreditation.

Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines. JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.4166

This entry was posted in Introduction. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s